Recent Updates
Recently added Catalysts
RXST Positive Sentiment Score: 70/100

RXSIGHT, INC. ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION Aliso Viejo, Calif. (Nasdaq: RXST)

Key Takeaway: RxSight, Inc. has announced that Shelley Thunen, the Chief Financial Officer, will transition from her role while continuing to support the company as a consultant. Thunen has been instrumental in RxSight's growth, guiding the company through pivotal financial milestones including its IPO in 2021. The leadership recognized her significant contributions in developing the company's financial strategy and achieving over 1,100 Light Delivery Devices in the field and a quarter million procedures performed. A successor will be appointed before her departure on January 31, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Shelley Thunen's long tenure and contributions were celebrated.
  • The transition is planned with continuity in mind, as she will remain as a consultant.
  • RxSight has experienced significant growth under her financial leadership.

Full Press Release Details

RXSIGHT, INC. ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION
Aliso Viejo, Calif. (Nasdaq: RXST) - December 22, 2025 - RxSight, Inc., an ophthalmic medical device company dedicated to
providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company's Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the
sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.
"Shelley has been a key and trusted partner throughout some of the most important years in RxSight's development," said Ron Kurtz, Chief
Executive Officer and President of RxSight. "Shelley developed and executed on our financial strategy, and over nearly a decade, her leadership and unwavering commitment helped guide RxSight from a pre-commerical company to one with more than
1,100 LDDs in the field and over a quarter million procedures performed. She has shaped the foundation we rely on today, and we are truly grateful for everything she has done for our patients, our customers, and everyone at RxSight."
"Shelley has had a profound impact on RxSight," said Andy Corley, Chairman of the Board. "Her judgment, integrity, and dedication helped
guide the Company through pivotal events, including our initial public offering in 2021, and positioned RxSight for the opportunities ahead. The Board is sincerely appreciative of her service and the lasting mark she leaves on the
Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised
of the RxSight Light Adjustable Lens (LAL /LAL+ , collectively the
"LAL"), RxSight Light Delivery Device (LDD ) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery,
enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Chief Financial Officer
Investor Relations Contact:
VP, Investor Relations

Frequently Asked Questions

Who is transitioning from CFO at RxSight?

Shelley Thunen is transitioning from her role as Chief Financial Officer.

When will Shelley Thunen leave her CFO position?

She will remain until a successor is appointed or by January 31, 2026.

What will Shelley Thunen do after her transition?

She has agreed to support the Company as a consultant after her transition.

What is RxSight's main focus?

RxSight specializes in customized vision solutions for cataract surgery patients.

What technology does RxSight use in their lenses?

They offer the Light Adjustable Lens system, adjustable post-surgery for better vision.

Last updated: Dec 22, 2025